Figure 4
Algorithm for management of newly diagnosed T-ALL. MA, myeloablative. *Adverse genetics include no NOTCH1/FBXW7 mutation or presence of N/K-RAS mutation and/or PTEN gene alteration. #Assess comorbidities and determine suitability for HCT.
Algorithm for management of newly diagnosed T-ALL. MA, myeloablative. *Adverse genetics include no NOTCH1/FBXW7 mutation or presence of N/K-RAS mutation and/or PTEN gene alteration. #Assess comorbidities and determine suitability for HCT.
